EMEA-002907-PIP01-20-M02
Key facts
| Active substance |
Epcoritamab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0415/2022
|
| PIP number |
EMEA-002907-PIP01-20-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of mature B-cell lymphoma
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|